The reiteration of the Outperform rating and maintenance of the $76 price target by Credit Suisse analyst Richard Law indicates a positive outlook for Intellia Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's performance and potential growth.